Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

A number of other equities analysts also recently issued reports on FDMT. Barclays reduced their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Bank of America dropped their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Chardan Capital decreased their price target on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group lowered their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Royal Bank Of Canada dropped their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Performance

FDMT traded up $0.44 on Friday, hitting $4.15. The company had a trading volume of 858,180 shares, compared to its average volume of 814,653. The stock has a market capitalization of $192.27 million, a price-to-earnings ratio of -1.31 and a beta of 2.81. The stock has a fifty day moving average price of $3.73 and a 200-day moving average price of $4.25. 4D Molecular Therapeutics has a 12-month low of $2.24 and a 12-month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. Analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of FDMT. Kera Capital Partners Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $89,000. Acadian Asset Management LLC raised its holdings in shares of 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock worth $1,290,000 after purchasing an additional 367,317 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics during the first quarter valued at $39,000. Millennium Management LLC boosted its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after purchasing an additional 213,264 shares during the last quarter. Finally, BVF Inc. IL grew its position in 4D Molecular Therapeutics by 70.8% during the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after purchasing an additional 1,890,647 shares during the period. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.